Medical Advisory Board additions support company’s growing product offerings across women’s health and family building. NEW ...

ERNA-101 remains on track for IND-enabling studies in 2025, with first-in-human studies targeted for 2026.

Columbia University, the Company’s collaboration partner for pre-clinical development, granted Silo an exclusive global license to further develop, manufacture, and commercialize SPC-15 worldwide.

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt ...

“I also want to thank Dale for his innumerable contributions to Outset during a critical period for the company. The experience, guidance and insights he brought to the board will have a lasting ...

THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted ...

The Dwayne Andrews Glioblastoma Research Grant has been made possible through the generous support of the Auto|One Group and The Andrews Family.

The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in ...